Daniel Christopher Rabe, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatocyte Growth Factor | 4 | 2015 | 270 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-met | 6 | 2016 | 578 | 0.310 |
Why?
|
| RNA, Satellite | 1 | 2022 | 17 | 0.220 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 3 | 2012 | 1114 | 0.200 |
Why?
|
| Cell-Derived Microparticles | 1 | 2023 | 168 | 0.200 |
Why?
|
| Phosphatidylethanolamine Binding Protein | 2 | 2016 | 11 | 0.170 |
Why?
|
| Hemin | 1 | 2019 | 49 | 0.170 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2019 | 154 | 0.160 |
Why?
|
| Exosomes | 1 | 2023 | 417 | 0.160 |
Why?
|
| RNA | 3 | 2023 | 2749 | 0.150 |
Why?
|
| Specimen Handling | 1 | 2021 | 694 | 0.140 |
Why?
|
| Microfluidics | 1 | 2020 | 662 | 0.120 |
Why?
|
| Cell Separation | 1 | 2020 | 1751 | 0.120 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 944 | 0.120 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 934 | 0.110 |
Why?
|
| Porifera | 1 | 2012 | 33 | 0.110 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2015 | 520 | 0.110 |
Why?
|
| Chemotaxis | 1 | 2015 | 607 | 0.100 |
Why?
|
| Neoplasm Metastasis | 4 | 2016 | 4851 | 0.100 |
Why?
|
| Metformin | 1 | 2019 | 835 | 0.100 |
Why?
|
| Piper | 1 | 2011 | 1 | 0.100 |
Why?
|
| Heparitin Sulfate | 1 | 2012 | 225 | 0.100 |
Why?
|
| Stromal Cells | 1 | 2016 | 1355 | 0.100 |
Why?
|
| Chemokines | 1 | 2015 | 970 | 0.100 |
Why?
|
| Anthozoa | 1 | 2011 | 62 | 0.090 |
Why?
|
| Diterpenes | 1 | 2011 | 173 | 0.090 |
Why?
|
| Anilides | 1 | 2013 | 408 | 0.090 |
Why?
|
| Alkaloids | 1 | 2011 | 190 | 0.090 |
Why?
|
| Receptors, Growth Factor | 1 | 2010 | 334 | 0.080 |
Why?
|
| Gene Targeting | 1 | 2012 | 880 | 0.080 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 3586 | 0.080 |
Why?
|
| Quinolines | 1 | 2013 | 732 | 0.080 |
Why?
|
| Prostate | 1 | 2016 | 1774 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 3616 | 0.070 |
Why?
|
| Cell Line, Tumor | 6 | 2022 | 16689 | 0.070 |
Why?
|
| Mice, Nude | 3 | 2019 | 3689 | 0.070 |
Why?
|
| Mitochondria | 1 | 2019 | 3520 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 4838 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2022 | 8428 | 0.060 |
Why?
|
| Pyrroles | 1 | 2011 | 1146 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2013 | 1333 | 0.060 |
Why?
|
| Biological Products | 1 | 2012 | 860 | 0.060 |
Why?
|
| RNA, Neoplasm | 2 | 2016 | 769 | 0.060 |
Why?
|
| Prostatic Neoplasms | 2 | 2016 | 11124 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 3703 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2015 | 23403 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 3508 | 0.050 |
Why?
|
| Macrophages | 1 | 2015 | 5655 | 0.050 |
Why?
|
| Leukapheresis | 1 | 2020 | 131 | 0.050 |
Why?
|
| Antineoplastic Agents | 3 | 2013 | 13695 | 0.040 |
Why?
|
| RNA Stability | 1 | 2021 | 321 | 0.040 |
Why?
|
| Culture Media | 1 | 2021 | 908 | 0.040 |
Why?
|
| Protein Isoforms | 2 | 2015 | 1730 | 0.040 |
Why?
|
| Neoplasms | 3 | 2012 | 21683 | 0.040 |
Why?
|
| Electron Transport | 1 | 2019 | 211 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 3557 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 2 | 2016 | 2012 | 0.040 |
Why?
|
| Citric Acid Cycle | 1 | 2019 | 232 | 0.040 |
Why?
|
| Plasma | 1 | 2021 | 575 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2022 | 713 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2012 | 3760 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2021 | 670 | 0.030 |
Why?
|
| Cyclohexanes | 1 | 2015 | 152 | 0.030 |
Why?
|
| HMGA2 Protein | 1 | 2015 | 123 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 2015 | 209 | 0.030 |
Why?
|
| Mice | 6 | 2019 | 81183 | 0.030 |
Why?
|
| Animals | 9 | 2019 | 168757 | 0.030 |
Why?
|
| Receptors, CCR5 | 1 | 2015 | 497 | 0.030 |
Why?
|
| Marine Biology | 1 | 2012 | 18 | 0.030 |
Why?
|
| Cadherins | 1 | 2016 | 907 | 0.030 |
Why?
|
| Plant Stems | 1 | 2011 | 19 | 0.020 |
Why?
|
| Humans | 15 | 2023 | 744343 | 0.020 |
Why?
|
| Plant Roots | 1 | 2011 | 109 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 1655 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2012 | 657 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2013 | 546 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2011 | 276 | 0.020 |
Why?
|
| Triazoles | 1 | 2015 | 911 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2011 | 563 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 20822 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 9438 | 0.020 |
Why?
|
| Protein Folding | 1 | 2012 | 843 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2015 | 13033 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2016 | 2382 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2012 | 1899 | 0.020 |
Why?
|
| Dogs | 1 | 2012 | 3912 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2012 | 970 | 0.020 |
Why?
|
| Glucose | 1 | 2019 | 4397 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3920 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 6386 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 3701 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 2715 | 0.020 |
Why?
|
| Phenotype | 1 | 2022 | 16365 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 6895 | 0.020 |
Why?
|
| Survival Rate | 1 | 2016 | 12788 | 0.010 |
Why?
|
| Female | 5 | 2022 | 380194 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 2635 | 0.010 |
Why?
|
| Protein Binding | 1 | 2012 | 9386 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 57776 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 21827 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2012 | 10481 | 0.010 |
Why?
|
| Prognosis | 1 | 2016 | 29063 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 4262 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 5535 | 0.010 |
Why?
|
| Male | 3 | 2016 | 350118 | 0.010 |
Why?
|
| Aged | 2 | 2016 | 163280 | 0.010 |
Why?
|
| Middle Aged | 2 | 2016 | 213383 | 0.010 |
Why?
|
| Adult | 2 | 2016 | 214055 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 11524 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2013 | 63114 | 0.000 |
Why?
|